Fulgent Genetics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Fulgent Genetics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

4.9%

Rendimento del riacquisto

Rendimento totale per gli azionisti	4.9%
Rendimento futuro dei dividendi	0%
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Sep 25

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Sep 09

Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Jul 17

Fulgent Genetics: Growth Is Returning

Jun 06

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di FLGT siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di FLGT siano aumentati.

Rendimento dei dividendi rispetto al mercato

Fulgent Genetics Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di FLGT rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (FLGT)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.2%
Media del settore (Healthcare)	1.6%
Analista previsionale (FLGT) (fino a 3 anni)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di FLGT rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di FLGT rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di FLGT per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché FLGT non ha segnalato alcun pagamento.

Fulgent Genetics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024

Fulgent Genetics: Growth Is Returning

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

COO & President recently sold US$583k worth of stock

COO & President notifies of intention to sell stock

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Price target decreased by 14% to US$36.50

Chief Financial Officer recently sold US$346k worth of stock

Chief Financial Officer notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

COO & President notifies of intention to sell stock

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Price target decreased by 7.4% to US$41.67

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Chief Financial Officer recently sold US$23k worth of stock

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold US$64k worth of stock

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Less than half of directors are independent

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Wait For Fulgent Genetics To Grow Up

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Chief Financial Officer recently sold US$95k worth of stock

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Chief Financial Officer recently sold US$64k worth of stock

Price target decreased to US$91.00

Fulgent Is Putting Its Cash Bonanza To Work